Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
About Athersys, Inc.
- NASDAQ: $ATHX
- Notified: $2.34
- 06:00 EDT
